Patient-reported outcomes in randomised controlled trials on age-related macular degeneration

British Journal of Ophthalmology

Volumn 99, Issue 11, 2015, Pages 1560-1564

  Krezel, Aniela K ^a   Hogg, Ruth E ^a   Azuara Blanco, Augusto ^a  

^a ROYAL VICTORIA HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AFLIBERCEPT; AGENTS ACTING ON THE EYE; ANECORTAVE; BEVACIZUMAB; BROMFENAC; DEXAMETHASONE; EYE DROPS; FENRETINIDE; KETOROLAC; MC 1101; PEGAPTANIB; RANIBIZUMAB; RAPAMYCIN; SQUALAMINE; TRIAMCINOLONE; UNCLASSIFIED DRUG;

AGE RELATED MACULAR DEGENERATION; APHERESIS; ARTICLE; BRACHYTHERAPY; CATARACT EXTRACTION; CLINICAL EFFECTIVENESS; CONTRAST SENSITIVITY; DARK ADAPTATION; DISEASE ACTIVITY; DRUG EFFICACY; EXTERNAL BEAM RADIOTHERAPY; HUMAN; HYPERTHERMIC THERAPY; MOVEMENT PERCEPTION; OUTCOME ASSESSMENT; PATIENT REPORTED OUTCOME MEASURE; PHOTODYNAMIC THERAPY; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RHEOHEMAPHERESIS; SYSTEMATIC REVIEW; TRANSCUTANEOUS NERVE STIMULATION; VISUAL ACUITY; MACULAR DEGENERATION; PATHOPHYSIOLOGY; PHYSIOLOGY; PSYCHOLOGY; QUESTIONNAIRE; SICKNESS IMPACT PROFILE;

HUMANS; MACULAR DEGENERATION; PATIENT OUTCOME ASSESSMENT; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SICKNESS IMPACT PROFILE; SURVEYS AND QUESTIONNAIRES; VISUAL ACUITY;

EID: 84945459565     PISSN: 00071161     EISSN: 14682079     Source Type: Journal    
DOI: 10.1136/bjophthalmol-2014-306544     Document Type: Article

References (23)

1. Velez-Montoya R, Oliver SC, Olson JL, et al. Current knowledge and trends in age-related macular degeneration: today's and future treatments. Retina 2013;33:1487-502.
2. O'Shaughnessy JA, Wittes RE, Burke G, et al. Commentary concerning demonstration of safety and efficacy of investigational anticancer agents in clinical trials. J Clin Oncol 1991;9:2225-32.
3. Food and Drug Administration (FDA). 2009. Patient reported outcome measures: use in medical product development to support labelling claims. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM193282.pdf (accessed 27 Mar 2015).
4. Bradley C. Feedback on the FDA's February 2006 draft guidance on Patient Reported Outcome (PRO) measures from a developer of PRO measures. Health Qual Life Outcomes 2006;4:78.
5. Byrne M. Cancer chemotherapy and quality of life. BMJ 1992;304:1523-4.
6. Ismail R, Azuara-Blanco A, Ramsay CR, et al. Variation of clinical outcomes used in glaucoma randomised controlled trials: a systematic review. Br J Ophthalmol 2014;98:464-8.
7. Slakter JS, Stur M. Quality of life in patients with age-related macular degeneration: impact of the condition and benefits of treatment. Surv Ophthalmol 2005;50:263-73.
8. Revicki DA, Rentz AM, Harnam N, et al. Reliability and validity of the National Eye Institute Visual Function Questionnaire-25 in patients with age-related macular degeneration. Invest Ophthalmol Vis Sci 2010;51:712-17.
9. Finger R, Fleckenstein M, Holz F, et al. Quality of life in age-related macular degeneration: a review of available vision-specific psychometric tools. Qual Life Res 2008;17:559-74.
10. Yuzawa M, Fujita K, Tanaka E, et al. Assessing quality of life in the treatment of patients with age-related macular degeneration: clinical research findings and recommendations for clinical practice. Clin Ophthalmol 2013;7: 1325-32.
11. Wiklund I. Assessment of patient-reported outcomes in clinical trials: the example of health-related quality of life. Fundam Clin Pharmacol 2004;18:351-63.
12. Vingolo E, Salvatore S, Limoli P. MP-1 biofeedback: luminous pattern stimulus versus acoustic biofeedback in age related macular degeneration (AMD). Appl Psychophysiol Biofeedback 2013;38:11-16.
13. Guyatt G, Veldhuyzen Van Zanten S, Feeny D, et al. Measuring quality of life in clinical trials: a taxonomy and review. CMAJ 1989;140:1441-8.
14. Massof R, Ahmadian L, Grover L, et al. The activity inventory: an adaptive visual function questionnaire. Optom Vis Sci 2007;84:763-74.
15. Aspinall P, Hill A, Dhillon B, et al. Quality of life and relative importance: a comparison of time trade-off and conjoint analysis methods in patients with age-related macular degeneration. Br J Ophthalmol 2007;91:766-72.
16. Moorfields Eye Hospital NHS Foundation Trust. EFFECT:Eccentric Fixation From Enhanced Clinical Training. ClinicalTrials.gov [Internet] 2011 (cited March 2014): NCT01499628
17. Berdeaux GH, Nordmann J, Colin E, et al. Vision-related quality of life in patients suffering from age-related macular degeneration. Am J Ophthalmol 2005;139:271-9.
18. Covert D, Berdeaux G, Mitchell J, et al. Quality of life and health economic assessments of age-related macular degeneration. Surv Ophthalmol 2007;52: S20-5.
19. Carta A, Braccio L, Belpoliti M, et al. Self-assessment of the quality of vision: association of questionnaire score with objective clinical tests. Curr Eye Res 1998;17:506-11.
20. Aaronson N. Quality of life assessment in clinical trials: methodologic issues. Control Clin Trials 1989;10:195-208S.
21. Aaronson N. Assessing the quality of life of patients in cancer clinical trials: Common problems and common sense solutions. Eur J Cancer 1992;28:1304-7.
22. Williamson P, Clarke M. The COMET (Core Outcome Measures in Effectiveness Trials) Initiative: its role in improving Cochrane reviews. Cochrane Database Syst Rev 2012;5:ED000041.
23. Owen CG, Rudnicka AR, Smeeth L, et al. Is the NEI-VFQ-25 a useful tool in identifying visual impairment in an elderly population? BMC Ophthalmol 2006;6:24-24.